Potential conflict of interest: Dr. Chung consults for Enanta and Idenix and received grants from Gilead, Massachusetts Biologics, Merck, and Vertex. Dr. Thomas consults and received grants from Gilead and Merck. He consults for Janssen. Dr. Sherman consults and received grants from Roche/Genentech. He consults for Janssen and Kadmon and received grants from Bristol-Myers Squibb and Merck. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. government.
Human immunodeficiency virus and liver disease forum 2012
Article first published online: 22 NOV 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 59, Issue 1, pages 307–317, January 2014
How to Cite
Sherman, K. E., Thomas, D. and Chung, R. T. (2014), Human immunodeficiency virus and liver disease forum 2012. Hepatology, 59: 307–317. doi: 10.1002/hep.26638
Funding for this conference was made possible, in part, by the National Institutes of Health (under award no. R13AI071925 from the National Institute of Allergy and Infectious Diseases), with cofunding from the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse. This work was supported by educational grants from Merck, Genentech, Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc. administered by Janssen Services, LLC, and Kadmon Pharmaceuticals, LLC.
- Issue published online: 20 DEC 2013
- Article first published online: 22 NOV 2013
- Accepted manuscript online: 31 JUL 2013 09:47AM EST
- Manuscript Accepted: 13 JUL 2013
- Manuscript Revised: 24 JUN 2013
- Manuscript Received: 2 MAY 2013
- 1The changing epidemiology of liver disease in HIV patients. AIDS Rev 2013;15:25–31., , .
- 3Continuum of HIV care: differences in care and treatment by sex and race/ethnicity in the United States. J Int AIDS Soc 2012;15:86–86., , , , , , et al.
- 6Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis 2011;17:1074–1078., , , , , , et al.
- 17The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther 2011;33:1234–1244., , , , .
- 33Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010;153:452–460., , .
- 35HIV, Age, and the severity of hepatitis C virus-related liver Disease: a cohort study. Ann Intern Med 2013;158:658–666., , , , , , et al.
- 37Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1–207; quiz, CE201-CE204., , , , , .
- 39The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl 2009;15:1133–1141., , , , , , et al.
- 43Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407–413., , , , , , et al.
- 44Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;169:86–96., , , , , , et al.
- 49Simeprevir with pegylated interferon/ribavirin in patients co-infected with chronic hepatitis C virus and HIV-1: week-24 interim analysis of the TMC435-C212 study (Abstract 154LB). Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA., , , , , , et al.
- 50STARTVerso 4: high rates of early virologic response in hepatitis C virus genotype 1/HIV co-infected patients treated with faldaprevir + pegylated interferon and ribavirin (Abstract 40LB). Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA., , , , , , et al.
- 51Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile which supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir (Abstract 618). In: 19th Conference on Retroviruses and Opportunistic Infections (CROI), March 5-8, 2012, Seattle, WA., , , , , , et al.
- 52HIV/HCV co-infected and HCV monoinfected patients have similar early hepatitis C viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA., , , , , , et al.
- 54Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol 2008;103:1810–1823., , , , , .Direct Link:
- 57Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol 2011;25:135–139., , , , .
- 60Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012;12:408–414., , , , , , et al.
- 61Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med 2010;152:704–711., , , , , , et al.